The widespread use of Prostate-specific antigen (PSA)-based early detection (opportunistic PSA-based screening) of prostate cancer (PCa) since the beginning of this century has led to a marked reduction in cancer-specific mortality (CSM) and a simultaneous increase in incidence (1). This evidence concerns the gene KLK3 and posterior cortical atrophy.